Pharmacokinetics of micafungin in critically ill patients with invasive candidiasis.

Phase 4

Completed

• Conditions: Invasive candidiasis; invasive fungal infection; 10017528

• Registration Number: NL-OMON37779
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Treatment with micafungin
Admission to an ICU
Age >= 18 years
Invasive candidiasis

Exclusion Criteria

Blood sampling not possible.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the correlation of the pharmacokinetic parameters<br /><br>and plasma concentration of micafungin with disease severity scores.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) Pharmacokinetic parameters of micafungin in ICU patients.<br /><br>2) Time (in days) to culture conversion.<br /><br>3) Correlation of the plasma concentration of micafungin with response to<br /><br>treatment.<br /><br>4) Correlation of the plasma concentration of micafungin with inflammation<br /><br>parameters.<br /><br>5) AUC/MIC ratio and Cmax/MIC ratio.<br /><br>6) Constructing a pharmacokinetic model of micafungin in critically ill<br /><br>patients.</p><br>